Nasal Obstruction Is Reduced 5–7 Years After Radiofrequency Turbinate Reduction: Results From a Retrospective Observational Cohort Study Authors: Veronica Ahlund, Pål Rosholm Comstedt, Maria Värendh, Pernilla Sahlstrand‐Johnson Published: 2026 ABSTRACT ABSTRACTIntroductionNasal obstruction, often caused by structural and inflammatory conditions, is prevalent and significantly impacts health‐related quality of life. Radiofrequency Turbinate Reduction (RFTR) is a widely employed treatment for inferior turbinate hypertrophy, yet evidence of its long‐term effectiveness remains limited. This study aimed to assess the patient‐perceived long‐term outcomes of RFTR in patients with nasal obstruction, focusing on quality of life as measured by the Sinonasal Outcome Test‐22 (SNOT‐22) and to identify baseline factors predicting surgical outcome.MethodsA cohort of 198 patients aged ≥ 18 years who underwent RFTR for nasal obstruction filled out the SNOT‐22 questionnaire and additional questions preoperatively and 5–7 years postoperatively. Predictors of persistent nasal obstruction after RFTR were identified using logistic regression analysis.ResultsSNOT‐22 scores significantly decreased from score mean 43.14 (0–104, min–max) to 34.66 (0–101) at the 5‐ to 7‐year follow‐up (p < 0.001), with notable improvements in the rhinologic and sleep function domains. However, baseline symptoms of ‘thick nasal discharge’ and ‘poor sleep quality’ were associated with a higher relative risk and higher odds ratio of continued nasal obstruction after adjustment for confounders. These baseline symptoms remained significant predictors of persistent nasal obstruction postoperatively.ConclusionRadiofrequency Turbinate Reduction reduced nasal obstruction and also showed long‐term efficacy in improving health‐related quality of life after long‐term outcome, with most patients reporting positive outcomes. Patients with severe baseline symptoms of thick nasal discharge and poor sleep quality may experience less favourable outcomes, possibly due to comorbidities. These findings highlight the potential of SNOT‐22 to identify patients at risk of persistent symptoms post‐RFTR. Introduction Nasal obstruction is a common symptom among patients referred to otorhinolaryngologists, with a variety of underlying causes, both anatomical and structural. Causes include septal deviation, nasal polyps, inferior turbinate hypertrophy, chronic rhinosinusitis and both allergic and non‐allergic rhinitis [1]. Nasal obstruction can significantly impact health‐related quality of life (HRQOL), leading to additional symptoms such as loss of smell and taste and impaired sleep quality [2]. Hypertrophy of the inferior turbinate is usually first treated with conservative methods such as intranasal steroids, antihistamines, sympathomimetics and, if unsuccessful, surgical turbinate interventions [3]. Radiofrequency Turbinate Reduction (RFTR) is one of the most common techniques for turbinate reduction [2] and is widely regarded as a safe and effective procedure [4, 5, 6, 7, 8]. The surgery involves submucosal tissue heating, leading to tissue fibrosis during the healing process, which results in a sustained reduction in turbinate volume over time [9]. Previous research has focused mainly on the short‐term outcomes of RFTR for isolated inferior turbinate hypertrophy [10, 11]. Long‐term studies are limited, typically covering a few years with small sample sizes [12, 13]. These studies, using both clinical assessments and patient‐reported outcomes, consistently show that RFTR leads to short‐term improvements in turbinate hypertrophy and nasal obstruction compared to controls [10, 11]. Positive effects from surgery have been reported to last up to 3 years [12, 13]. Various patient‐reported outcome measures have been used to evaluate the effectiveness of RFTR. The 22‐item Sino‐Nasal Outcome Test (SNOT‐22) is a validated questionnaire originally developed to assess the impact of chronic rhinosinusitis (CRS) [14] and has also been utilised to evaluate septoplasty outcomes [15]. Although SNOT‐22 has not yet been validated for use following RFTR, it may still offer clinically relevant insights as a quality‐of‐life assessment tool, particularly in view of the currently limited number of validated alternatives available for this purpose. The primary aim of the present study was to investigate the long‐term effectiveness of RFTR in a larger cohort of patients with nasal obstruction, using SNOT‐22 to measure both nasal blockage and quality of life. A secondary aim was to identify factors from the baseline scoring of SNOT‐22 that could predict a lack of improvement in nasal obstruction after RFTR. The study hypothesised that the positive effects observed postoperatively would not be sustained over an extended period. Material and Methods Study Population and Design Patients aged ≥ 18 years with nasal obstruction who had not responded adequately to nasal steroids after a recommended treatment period of 2 months and in whom clinical examination demonstrated hypertrophy of the inferior turbinates were referred for RFTR at Skane University Hospital, between 8 March 2011 and 30 June 2013. Patients with other conditions causing nasal obstruction, such as nasal septum deviation or internal/external nasal valve collapse or stenosis, were excluded from the current study and referred for surgery addressing those specific issues. These RFTR patients were all offered the opportunity to fill out the SNOT‐22 questionnaire prior to surgery. In total, 290 patients completed the questionnaires prior to RFTR. They were subsequently contacted by mail and invited to participate in a long‐term follow‐up 5–7 years post‐surgery. Reminders were sent by mail and patients were also called if there was no response. Along with the SNOT‐22, the patients received an additional questionnaire addressing health‐related conditions that included questions about their experience of the RFTR treatment, allergies, body measurements and comorbidities. The SNOT‐22 and the accompanying questionnaire, along with written informed consent, were returned to the study coordinator and data were recorded anonymously in a database. In 2018, the Regional Ethics Review Board in Lund (registration number 2018/976) approved the study protocol. Radiofrequency Turbinate Reduction (RFTR) All patients were treated with the same procedure by one of three surgeons. The inferior turbinate was topically anaesthetised using local anaesthesia (Carbocain without adrenaline) in an outpatient facility. The radio frequency energy was delivered with a handheld bipolar probe with two needles, set at bipolar coagulation mode, inserted in the mucosa along the full length of the inferior turbinate, producing a temperature of 60°C–90°C. The radiofrequency generator was a Sutter, BM‐780 II Radiofrequency Unit, D‐79108 Freiburg, Germany. The procedure is known to be well tolerated under local anaesthesia [16]. Sinonasal Outcome Test‐22 The Sinonasal Outcome Test‐22 (SNOT‐22) is a health‐related quality of life (HRQOL) questionnaire derived from the SNOT‐20, originally developed by Piccirillo et al. in 2002 [17]. Two additional questions were incorporated to address nasal blockage and the loss of sense of taste and smell [17]. Each of the 22 criteria is scored on a scale from 0 to 5, yielding a total score range from 0 to 110, where lower scores indicate a better HRQOL. Although SNOT‐22 was initially designed for use in patients with chronic rhinosinusitis (CRS), it has become a widely used instrument for evaluating outcomes in various procedures [14, 18, 19]. The questionnaire has been translated and validated in multiple languages, including Swedish [20]. To facilitate clinical interpretation and focus on disease‐specific symptoms, SNOT‐22 is divided into four domains: rhinology (items 1, 2, 3, 4, 5, 7 and 8), ear/facial symptoms (items 6, 9, 10, 11 and 12), sleep function (items 13, 14, 15 and 16) and psychological issues (items 17, 18, 19, 20, 21 and 22) [21]. Characteristics of the Patients and Medical History A health‐related questionnaire was also distributed at the 5–7‐year follow‐up. The questionnaire included 11 relevant questions with response options categorised as affirmative, negative and unknown. Statistical Analysis The results from all items on the SNOT‐22 questionnaire were presented as mean values. The Wilcoxon signed‐rank test was used to assess the significance of differences between the mean SNOT‐22 scores obtained preoperatively and at the five‐ to seven‐year postoperative follow‐up. In addition, the median total SNOT‐22 score was calculated together with interquartile range (IQR) for both the preoperative assessment and the five‐ to seven‐year postoperative follow‐up. Subsequently, responses were categorised based on the percentage of patients reporting severe symptoms. Responses were dichotomised into two categories: severe and mild. A severe condition was defined as a score of 4–5 on the relevant SNOT‐22 item, whereas a mild condition was defined as a score of 0–3. The Chi‐square test was applied to evaluate the significance of differences between these categories—severe and mild—when comparing preoperative and postoperative SNOT‐22 scores. The SNOT‐22 item on severe nasal blockage at the 5–7 year follow‐up was dichotomised into severe and mild blockage to identify preoperative predictors of outcome. Preoperative SNOT‐22 responses were compared between groups, categorising each criterion as severe versus non‐severe. Differences were expressed as relative risk. The McNemar test was used to compare severe versus mild nasal obstruction at the 5–7 year follow‐up with the corresponding severe versus mild conditions for all SNOT‐22 questions in the preoperative setting. Additionally, an odds ratio was calculated for the 10 items that demonstrated the highest relative risk. Multiple regression analysis was subsequently performed to evaluate factors that could predict persistent nasal obstruction 5–7 years after surgery. Simple mean imputation was used for missing data in SNOT‐22 [22]. The mean value of the available responses was calculated and used to fill in the missing items, provided that at least 50% of the questions had been answered. A two sided p‐value ≤ 0.05 was considered significant. All analyses were conducted using SPSS version 29.0.0.0. Results A total of 295 patients aged ≥ 18 completed the preoperative SNOT‐22. Five were excluded due to incomplete responses (< 50% answered). The study flow is shown in Figure 1. At the 5‐year follow‐up, 92 patients did not respond, leaving 198 patients (81 female) with a mean age of 43 years (min–max 18–77). Simple mean imputation was applied to 45 preoperative cases (16%) and 15 follow‐up cases (8%) with missing data. On average, fewer than two items were missing per incomplete questionnaire at both time points. Flowchart of the study inclusion of patients with the age ≥ 18 years. RFTR, radiofrequency turbinate reduction, surgery; SNOT‐22, Sinonasal Outcome Test. The response rate after 5–7 years was 68% (n = 198). There were no sex differences between responders and non‐responders (p = 0.45), nor in mean SNOT‐22 scores (p = 0.08). However, non‐responders were significantly younger than responders (33 vs. 43 years, p < 0.001). Although only 69 patients (35%) were satisfied with the surgery, according to the patient medical characteristics questionnaire, 129 (65%) would undergo it again (Table 1). Analysis of the dichotomised groups showed that 29% of those with mild nasal obstruction were satisfied, compared to 6% of those with severe obstruction. TABLE 1Patient characteristics and medical history. n = 198AffirmativeNegativeUnknownSatisfied with RFTR35%47%18%Would still do it with current knowledge65%32%3%Other RFTR24%76%0%Other nasal surgery post RFTR10%90%0%Allergy32%48%20%Snore61%23%16%Sleep apnea19%77%4%Hypertension23%75%2%Pulmonary condition16%77%8%Heart condition9%88%4%AffirmativeNegativePreviousSmoker8%72%20%MeanMinMaxHeight (m)1.751.561.95Weight (kg)80.242145BMI26.0815.2444.53 Note: Patient characteristics and medical history as patient reported in questionnaire regarding health‐related conditions after 5–7 years.Abbreviations: BMI, body mass index; n, number of patients; RFTR, radiofrequency turbinate reduction. Patient characteristics and medical history. Note: Patient characteristics and medical history as patient reported in questionnaire regarding health‐related conditions after 5–7 years. Abbreviations: BMI, body mass index; n, number of patients; RFTR, radiofrequency turbinate reduction. The total SNOT‐22 score significantly decreased from a mean of 43.14 (range 0–104) preoperatively to 34.66 (0–101) 5–7 years postoperatively (p < 0.001). In terms of the median, the total SNOT‐22 score decreased from 41 to 31, with an interquartile range (IQR) of 27 preoperatively and 34 5–7 years postoperatively. There was an improvement in the criterion related to nasal blockage/congestion. All individual SNOT‐22 item scores, except for four ‘runny nose’, ‘dizziness’, ‘facial pain/pressure’ and ‘sad’, decreased significantly (p < 0.05) (Table 2). TABLE 2SNOT‐22 mean score.Preoperative scorePostoperative score 5 yearsChange p 1.Need to blow nose2.862.43−0.43 < 0.001 2.Sneezing1.891.62−0.28 0.004 3.Runny nose2.071.93−0.140.1614.Blockage/congestion of nose3.822.84−0.98 < 0.001 5.Sense of taste/smell1.791.39−0.40 < 0.001 6.Cough1.371.12−0.25 0.013 7.Post nasal discharge2.271.84−0.42 < 0.001 8.Thick nasal discharge1.691.19−0.49 < 0.001 9.Ear fullness1.561.20−0.36 0.003 10.Dizziness0.810.76−0.050.58711.Ear pain0.720.47−0.25 0.007 12.Facial pain/pressure0.890.79−0.100.26513.Difficulty falling asleep1.881.36−0.52 < 0.001 14.Waking up at night2.542.19−0.35 0.007 15.Lack of a good night's sleep2.462.05−0.41 0.001 16.Waking up tired2.972.37−0.60 < 0.001 17.Fatigue2.552.10−0.44 < 0.001 18.Reduced productivity1.91.56−0.34 0.003 19.Reduced concentration1.781.45−0.33 0.004 20.Frustrated/restless/irritable1.861.31−0.55 < 0.001 21.Sad1.011.030.020.94222.Embarrassed2.451.66−0.79 < 0.001 Total43.1434.66−8.48 < 0.001 Note: The actual scores of SNOT‐22 depicted prior to surgery and 5–7 years after RFTR, showing improvement in nasal obstruction and in all items except for four, 5–7 years after surgery. n = 198 patients. Bold values indicate statistical significance (p < 0.05). SNOT‐22 mean score. Note: The actual scores of SNOT‐22 depicted prior to surgery and 5–7 years after RFTR, showing improvement in nasal obstruction and in all items except for four, 5–7 years after surgery. n = 198 patients. Bold values indicate statistical significance (p < 0.05). Analysis of the dichotomised data, comparing the percentage of patients rating > 3 (severe condition) versus 0–3 (mild condition) for each criterion, revealed significant changes (p < 0.05) at the 5–7 year follow‐up. The rhinological domain showed changes 5–7 years post‐surgery (Figure 2). Additionally, the sleep function domain demonstrated significant improvements, with a shift from severe to mild conditions 5–7 years after RFTR. Patients who scored severe conditions in the rhinologic domain of SNOT‐22 showed significant differences (< 0.05) in all criteria, apart from blockage of nose, in the scores before RFTR compared to 5–7 years later. Due to the dichotomisation into the two groups, severe and mild condition and the fact that chi square compares four groups, which in this case were too similar, we could not show any statistical significance in blockage of nose, although a clear difference was observed. Analysis of the five‐ to seven‐year outcome of RFTR for nasal blockage, the primary indication for surgery, showed that 113 out of 198 patients rated their nasal obstruction as 1–3 (mild). The remaining 85 patients rated their obstruction as 4–5 (severe). Preoperatively, there were 54 patients with mild nasal obstruction and 144 patients with severe nasal obstruction. We have performed a sensitivity analysis excluding the 10% who had undergone additional nasal surgery and the mean SNOT‐22 result did not change. The relative risk of severe nasal obstruction at the five‐ to seven‐year follow‐up was assessed by comparing all baseline SNOT‐22 scores for severe conditions between patient groups experiencing mild and severe nasal obstruction 5–7 years post‐RFTR. A relative risk greater than 1.5 was considered indicative of an increased likelihood of persistent severe nasal obstruction. Ten SNOT‐22 criteria showed a significantly higher relative risk (RR > 1.5) for severe nasal obstruction after 5–7 years, when baseline scores were for severe conditions (Table 3). TABLE 3Relative risk severe condition.Severe condition (score 4–5) for the SNOT‐22 items at baselineSevere nasal obstruction at 5 yearsMild nasal obstruction at 5 yearsMcNemarRelative risk n = 85 n = 113 p 1. Need to blow nose47%28%0.1711.662. Sneezing18%15%< 0.0011.173. Runny nose25%13%< 0.001 1.86 4. Blockage/congestion of nose79%68%< 0.0011.165. Sense of taste/smell21%13%< 0.001 1.60 6. Cough9%11%< 0.0010.897. Post nasal discharge34%26%0.0051.338. Thick nasal discharge24%12%< 0.001 1.90 9. Ear fullness15%16%< 0.0010.9610. Dizziness8%6%< 0.0011.3311. Ear pain5%4%< 0.0011.0612. Facial pain/pressure11%6%< 0.001 1.71 13. Difficulty falling asleep28%15%< 0.001 1.88 14. Waking up at night41%30%0.1011.3715. Lack of a good night's sleep41%25%0.017 1.66 16. Waking up tired52%43%0.4611.1917. Fatigue34%28%0.0141.2018. Reduced productivity25%13%< 0.001 1.86 19. Reduced concentration16%10%< 0.001 1.69 20. Frustrated/restless/irritable21%12%< 0.001 1.84 21. Sad9%3%< 0.001 3.55 22. Embarrassed35%33%< 0.0011.08 Note: Comparison of the two groups for severe versus mild nasal obstruction after 5–7 years. The values represent severe condition (4–5 score) response rates at baseline for each item (n = 198). p < 0.05 is considered statistically significant. Bold values indicate statistically significant SNOT‐22 items with RR > 1.5. Relative risk severe condition. Note: Comparison of the two groups for severe versus mild nasal obstruction after 5–7 years. The values represent severe condition (4–5 score) response rates at baseline for each item (n = 198). p < 0.05 is considered statistically significant. Bold values indicate statistically significant SNOT‐22 items with RR > 1.5. To determine the odds of persistent severe nasal obstruction (scoring 4–5) at the five‐ to seven‐year follow‐up, odds ratios (OR) were calculated for these 10 SNOT‐22 criteria. Five of the 10 items showed statistically significant associations in the unadjusted analysis. After adjusting for confounders, including smoking, allergy and sex, two items, ‘Thick nasal discharge’ and ‘Lack of a good night's sleep’ remained significant (Table 4). TABLE 4Odds ratio severe condition.Unadjusted odds ratio (95% CI) p‐value for group differenceAdjusted odds ratio (95% CI) p‐value for group difference3. Runny nose2.14 (1.03–4.47) 0.04 2.33 (0.84–6.48)0.15. Sense of taste/smell1.76 (0.83–3.73)0.141.48 (0.51–4.30)0.478. Thick nasal discharge2.18 (1.03–4.61) 0.04 3.02 (1.10–8.28) 0.03 12. Facial pain/pressure1.79 (0.64–5.03)0.271.18 (0.26–5.29)0.8313. Difficult falling asleep2.22 (1.10–4.47) 0.03 1.36 (0.53–3.50)0.5215. Lack of a good night's sleep2.13 (1.16–3.90) 0.02 2.49 (1.06–5.85) 0.04 18. Reduced productivity2.25 (1.03–4.47) 0.04 1.99 (0.71–5.58)0.1919. Reduced concentration1.83 (0.79–4.26)0.161.46 (0.49–4.37)0.520. Frustrated/restless/irritable2.07 (0.95–4.50)0.072.63 (0.86–8.03)0.0921. Sad3.81 (0.98–14.82)0.0543.66 (0.63–21.30)0.15 Note: Prediction of severe nasal obstruction after 5–7 years depending on severe SNOT‐22 criterion grading at baseline. OR calculated for the difference between the two groups, severe versus mild nasal obstruction after 5–7 years, for the 10 SNOT‐22 criteria with RR > 1.5. Calculations made for unadjusted as well as adjusted OR (n = 198 patients). Bold values indicate statistical significance (p < 0.05). Odds ratio severe condition. Note: Prediction of severe nasal obstruction after 5–7 years depending on severe SNOT‐22 criterion grading at baseline. OR calculated for the difference between the two groups, severe versus mild nasal obstruction after 5–7 years, for the 10 SNOT‐22 criteria with RR > 1.5. Calculations made for unadjusted as well as adjusted OR (n = 198 patients). Bold values indicate statistical significance (p < 0.05). Discussion In this retrospective cohort study, a significant improvement in nasal obstruction measured by HRQOL assessments through SNOT‐22 was still evident at 5–7 years post RFTR. Our primary aim was met and we demonstrated the long‐term effectiveness of RFTR treatment. We identified factors from the baseline scoring that could predict lack of improvement, which was our secondary aim. We hypothesised that the positive postoperative effects would diminish over time. However, we were surprised to find the improvements proved to be sustained in the long term. In the current study, the patients had poor quality of life related to nasal health symptom (SNOT‐22 mean scores 43.14) preoperatively. Other nasal surgery studies involving patients with similarly elevated preoperative SNOT‐22 scores have reached comparable conclusions [18]. There was a statistically significant improvement in nasal obstruction and HRQOL measured by SNOT‐22 5–7 years after RFTR and this improvement was observed in approximately 80% of the SNOT‐22 criteria. Previous studies in patients with chronic rhinosinusitis have identified a minimal clinical difference of total SNOT‐22 score as mean 8.9 units [14, 23]. In this study, involving patients treated with RFTR for nasal obstruction, the mean total difference in SNOT score was 8.48 units and the median total difference 10 units, respectively. In relation to other studies, this change can be considered to be clinically meaningful. The key symptom in this population was nasal blockage and there was indeed a decrease by one unit in the item ‘Blockage/congestion of nose’ of SNOT‐22. Several previous studies have reported similar short‐term HRQOL improvements up to 1 year post‐ RFTR [3, 6], as well as long‐term benefits extending up to three years [9, 12, 13]. These studies utilised VAS or SNOT‐22 as assessment, with sample sizes ranging from 19 to 92 patients. However, there is a notable scarcity of studies with larger sample sizes and longer follow‐up periods. No other studies reporting a five‐ to seven‐year follow‐up post‐ RFTR were identified in the literature. Data dichotomised based on degree of improvement have been utilised to evaluate RFTR outcomes. One such study reported HRQOL improvements similar to our findings but with a follow‐up limited to 1 year [24]. Previous research has investigated factors that influence the outcome of RFTR. Predictors such as anterior septal deviation, allergies and asthma have been associated with less favourable long‐term outcomes, whereas older age and non‐smoking status have been linked to improved long‐term outcomes [24, 25]. These studies primarily focused on patient characteristics and medical history as predictors. In contrast, our study analysed HRQOL conditions at baseline, using the SNOT‐22 questionnaire as a potential predictive tool for RFTR outcomes. Thus, RFTR appears to result in subjective long‐term improvements in nasal obstruction and quality of life. When investigating factors influencing remaining nasal symptoms our analysis identified severe symptoms in 10 items that demonstrated a significant relative risk (> 1.5) of refractory severe nasal obstruction. A high score in the questions ‘Thick nasal discharge’ and ‘Lack of a good night's sleep’ preoperatively was predictive of a higher odds of insufficient response to RFTR for nasal obstruction after surgery. It can be hypothesised that patients scoring high on the item ‘Thick nasal discharge’ may suffer from chronic rhinosinusitis, for which RFTR may not be an appropriate treatment option, alternatively extended treatment planning. Similarly, ‘Lack of a good night's sleep’ could reflect underlying sleep disturbances, such as obstructive sleep apnoea or insomnia. These patients may benefit from managing their sleep disturbances with targeted treatment before assessing nasal obstruction and selecting the most appropriate treatment approach. Although two thirds of the cohort stated they would undergo the procedure again with their current knowledge, only a bit over one third reported actually being satisfied with the RFTR treatment. This suggests that while the surgery may provide measurable, meaningful symptom relief on the SNOT‐22, it routinely fails to meet the subjective definitions of a successful or complete outcome for the patients. The satisfaction of the patients might depend on factors beyond symptom reduction alone, such as residual complaints, comorbid conditions, or unmet expectations. Or is it possible that the patients believe that another surgery might give even more symptom relief? The fact that a majority of patients would nevertheless choose to undergo the procedure again indicates that the perceived benefit was meaningful, despite insufficiency to meet the subjective definition of treatment success for the patients. These findings highlight the importance of thorough preoperative patient counselling, with an emphasis on setting realistic expectations and clarifying that partial rather than complete symptom resolution is the most likely outcome. Our study has demonstrated the long‐term positive effect of RFTR on nasal obstruction. Additionally, we investigated the potential of utilising HRQOL questionnaires to identify predictors of treatment failure to reduce nasal blockage through RFTR. Among the SNOT‐22 criteria, scoring high in ‘Thick nasal discharge’ and ‘Lack of a good night's sleep’ were identified as significant risk factors. However, further research is needed to establish a comprehensive and reliable list of other predictive factors. A major strength of this study is the use of a validated and relevant questionnaire, providing detailed insights into nasal symptoms and related issues, such as sleep quality. Additionally, while the relatively large sample size allows for a robust analysis of symptom prevalence and patterns within the studied cohort, one should be careful when considering generalisation to the general population. Important factors such as race, ethnicity and age groups were not specifically accounted for, which limits the applicability of the results across more diverse populations. Unlike a strictly selected research cohort, this study reflects real‐world clinical settings, which can be viewed as both a strength and a limitation. One primary limitation of the study is the reliance on subjective, patient‐reported outcomes, which lack the objectivity of physiological measures. While the SNOT‐22 captures patient‐perceived symptom burden and health‐related quality of life, it does not provide objective information on nasal airflow or anatomical changes. The absence of objective assessments, such as rhinomanometry or peak nasal inspiratory flow, limits the ability to correlate subjective improvement with measurable changes in nasal patency. However, the results are derived from a validated tool, giving important patient perspectives. Future studies should pair patient‐reported outcome measures with objective physiological measures to better assess efficacy and clarify long‐term outcomes. The absence of a control group is another important limitation. Although the inclusion of a non‐treated control group would have strengthened causal inference and improved the reliability of the findings, ethical considerations complicate such study designs, as patients were selected for surgery due to insufficient response to medical therapy. Nevertheless, without a control group, it cannot be definitively proven that the sustained improvement over 5–7 years is caused by the RFTR. Natural disease fluctuations, regression to the mean, or the effects of concomitant medical treatments cannot be ruled out in this study but can be addressed in future ones. A further limitation of this study is the lack of detailed diagnostic information, including comorbid conditions and the duration of prior medical treatment. Factors like one fifth reporting sleep apnoea and one third reporting allergies might influence rhinologic and sleep domains of the SNOT‐22 and treatment outcomes. However, the cohort reflects typical clinical practice, where patients selected for RFTR generally present with nasal obstruction due to a combination of turbinate hypertrophy and rhinitis, making the study population representative of those who routinely undergo this procedure. A further limitation of this study is the lack of detailed diagnostic information, including comorbid conditions and the duration of prior medical treatment; factors such as roughly one fifth reporting sleep apnoea and one third reporting allergies may influence the rhinologic and sleep domains of the SNOT‐22 and, consequently, treatment outcomes. The cohort reflects typical clinical practice, where patients selected for RFTR generally present with nasal obstruction due to a combination of turbinate hypertrophy and rhinitis, making the study population representative of those who routinely undergo this procedure. Additionally, up to 25% had prior nasal surgery and 10% underwent further surgery after RFTR, complicating attribution of long‐term quality‐of‐life gains to RFTR alone. This nevertheless reflects routine practice with multiple treatments before RFTR. The findings suggest repeated RFTR may be preferable in cases of recurrence. A sensitivity analysis excluding the 10% showed no change in the mean SNOT‐22. An additional constraint is the loss of one third to follow‐up and also the observed age difference between responders and non‐responders. Although the overall response rate was acceptable for a long‐term follow‐up study, non‐responders were significantly younger than responders. This age‐related response pattern introduces a potential risk of response bias, as older patients may differ from younger patients in symptom perception, treatment expectations and long‐term disease progression. Previous studies have shown that older patients are more likely to respond and also more likely to report lower scores than younger patients [26]. This may have contributed to an overestimation of the perceived long‐term efficacy of RFTR. Consequently, the results are less generalisable to younger populations, so future studies should minimise loss to follow‐up and ensure age‐balanced response rates. Despite these limitations, with the validated QoL tool, the findings provide a meaningful foundation for future research and can support clinical decision making. As part of the broader context of nasal surgery, it is relevant to note that RFTR is one frequently used rhinosurgical method. Other methods to be mentioned are total and partial turbinectomy which can improve obstruction but are associated with higher rates of crusting, bleeding and impaired turbinate function. More conservative methods such as laser, electrocautery and cryotherapy have variable complication profiles and limited effect. Turbinate out fracture alone has not shown reliable efficacy [27]. Among submucosal techniques, coblation is a gentle, low‐risk method based on a plasma‐mediated, low‐temperature process. When comparing to RFTR, both techniques are associated with minimal complications and limited postoperative discomfort and have been shown to provide improvements in airflow and symptoms [28]. Microdebrider‐assisted resection, on the other hand, may yield more durable outcomes but at the expense of greater invasiveness and higher risk of bleeding or synechiae [29]. In this context, RFTR remains a practical and widely used option, combining efficacy with low complication rates and technical simplicity. Importantly, as previous studies have not consistently demonstrated long‐term effectiveness, largely due to small cohorts and short follow‐up [28], the present study was undertaken to address this gap and demonstrates that RFTR treatment provides sustained long‐term benefit. These findings underline the importance of evaluating the long‐term outcomes of comparable techniques in future research. Conclusion Radiofrequency Turbinate Reduction reduced nasal obstruction and showed long‐term efficacy in improving health‐related quality of life 5–7 years postoperatively, in a large majority of the patients. Patients' baseline symptoms of thick nasal discharge and poor sleep quality may experience less favourable outcomes, possibly due to comorbidities. These findings highlight the potential of SNOT‐22 to identify patients at risk of persistent symptoms post‐RFTR when considering patients prior to surgery. Author Contributions V.A., P.R.C., M.V. and P.S.‐J. planned the project. P.R.C. collected the data and obtained ethical approval. V.A. analysed the data and wrote the manuscript. M.V. and P.S.‐J. supervised the project and reviewed the manuscript. Funding The authors have nothing to report. Ethics Statement From an ethical point of view it is important to evaluate the outcome of the often performed procedure Radiofrequency Turbinate Reduction (RFTR) and thereby improve treatment for patients. All patients signed an informed consent and data were de‐identified in a database to assure anonymity. The Regional Ethics Review Board at Lund University (registration number 2018/976) has approved the study protocol. Consent Patients have signed a written informed consent. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supporting Information: S1 Patients scoring severe conditions in the sleep function domain, showing significant improvement for all criteria (p < 0.05).